JP7777532B2 - 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子 - Google Patents

線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子

Info

Publication number
JP7777532B2
JP7777532B2 JP2022544144A JP2022544144A JP7777532B2 JP 7777532 B2 JP7777532 B2 JP 7777532B2 JP 2022544144 A JP2022544144 A JP 2022544144A JP 2022544144 A JP2022544144 A JP 2022544144A JP 7777532 B2 JP7777532 B2 JP 7777532B2
Authority
JP
Japan
Prior art keywords
mydgf
protein
fibrosis
mice
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511358A5 (https=
JP2023511358A (ja
JPWO2021148411A5 (https=
Inventor
クリストフ ヴォラート，カイ
コーフ－クリンゲビール，モルティマー
エル レボル，マルク
ペクセック，アントン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023511358A publication Critical patent/JP2023511358A/ja
Publication of JP2023511358A5 publication Critical patent/JP2023511358A5/ja
Publication of JPWO2021148411A5 publication Critical patent/JPWO2021148411A5/ja
Application granted granted Critical
Publication of JP7777532B2 publication Critical patent/JP7777532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022544144A 2020-01-21 2021-01-19 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子 Active JP7777532B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20153008 2020-01-21
EP20153008.6 2020-01-21
PCT/EP2021/051079 WO2021148411A1 (en) 2020-01-21 2021-01-19 Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure

Publications (4)

Publication Number Publication Date
JP2023511358A JP2023511358A (ja) 2023-03-17
JP2023511358A5 JP2023511358A5 (https=) 2024-01-26
JPWO2021148411A5 JPWO2021148411A5 (https=) 2024-01-26
JP7777532B2 true JP7777532B2 (ja) 2025-11-28

Family

ID=69187588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544144A Active JP7777532B2 (ja) 2020-01-21 2021-01-19 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子

Country Status (12)

Country Link
US (1) US20230059560A1 (https=)
EP (1) EP4093750A1 (https=)
JP (1) JP7777532B2 (https=)
KR (1) KR20220131262A (https=)
CN (1) CN115698048A (https=)
AU (1) AU2021211874A1 (https=)
BR (1) BR112022014272A2 (https=)
CA (2) CA3164500A1 (https=)
MX (1) MX2022008727A (https=)
PH (1) PH12022551792A1 (https=)
TW (1) TW202142254A (https=)
WO (1) WO2021148411A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066729A1 (en) * 2020-09-22 2022-03-31 Wisconsin Alumni Research Foundation Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor
US20250325704A1 (en) 2020-12-23 2025-10-23 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
CN115820829B (zh) * 2022-03-22 2026-04-17 中国人民解放军军事科学院军事医学研究院 Mydgf在防治记忆损伤及其相关疾病中的应用
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
JP2025530232A (ja) 2022-09-08 2025-09-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心原性ショックの処置に用いる骨髄由来成長因子
EP4480490A1 (en) * 2023-06-23 2024-12-25 Medizinische Hochschule Hannover Brick1 for use in treating myocardial diseases
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506484A (ja) 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US20080004232A1 (en) 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP2130547A1 (en) 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
DK2945642T3 (da) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
WO2020176732A1 (en) * 2019-02-27 2020-09-03 Icahn School Of Medicine At Mount Sinai TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506484A (ja) 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法

Also Published As

Publication number Publication date
PH12022551792A1 (en) 2023-09-18
EP4093750A1 (en) 2022-11-30
MX2022008727A (es) 2022-10-07
CA3164500A1 (en) 2021-07-29
AU2021211874A1 (en) 2022-08-25
WO2021148411A1 (en) 2021-07-29
KR20220131262A (ko) 2022-09-27
TW202142254A (zh) 2021-11-16
JP2023511358A (ja) 2023-03-17
CN115698048A (zh) 2023-02-03
US20230059560A1 (en) 2023-02-23
CA3223879A1 (en) 2021-07-29
BR112022014272A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
JP7777532B2 (ja) 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子
Iwanaga et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats
Muro et al. An essential role for fibronectin extra type III domain A in pulmonary fibrosis
David et al. Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality
Hunley et al. Update on endothelins–biology and clinical implications
US20070167386A1 (en) Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same
AU2018297274B2 (en) Treatment of heart disease by inhibition of the action of muscle A-kinase anchoring protein (mAKAP)
Yang et al. LncRNA CCRR maintains Ca2+ homeostasis against myocardial infarction through the FTO-SERCA2a pathway
JPWO2004022753A1 (ja) アクチン関連新規細胞骨格タンパク質ｌａｃｓ
US20160038568A1 (en) Treatment of heart disease by inhibition of the action of ribosomal s6 kinase 3 (rsk3)
WO2017029206A1 (en) Use of k2p potassium channel for altering the electrophysiology of the heart
US11944671B2 (en) Hippo pathway deficiency reverses systolic heart failure post-infarction
JP2026506629A (ja) 心臓機能を改善するための変異体ｙａｐの使用
EA053022B1 (ru) Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности
WO2024052563A1 (en) Myeloid-derived growth factor for use in treating cardiogenic shock
Yang et al. Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation
HK40088501A (zh) 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
US20250345404A1 (en) Compositions and methods for treating heart failure
Lucas et al. Gadd45g regulates cardiomyocyte death and post-myocardial infarction left ventricular remodelling
Slyke et al. Effects of a synthetic PEG-ylated Tie-2 agonist peptide
Class et al. Patent application title: TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3) Inventors: Michael S. Kapiloff (Miami Beach, FL, US) Jinliang Li (Miami, FL, US) Michael Kritzer (Miami, FL, US) Catherine Passariello (Miami, FL, US) Kimberly Dodge-Kafka (Unionville, CT, US) Assignees: ANCHORED RSK3 INHIBITORS, LLC
JP2012012330A (ja) 癌転移抑制剤及び医薬組成物
EP2874629A1 (en) Inhibitors of nkx2.5 for vascular remodelling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251117

R150 Certificate of patent or registration of utility model

Ref document number: 7777532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150